8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Cancer & Tumors242 citations

Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer

Bioeffects Seen

Authors not listed · 1982

Share:

Lower nighttime melatonin levels correlate with estrogen-positive breast cancer, highlighting EMF's role in disrupting protective hormones.

Plain English Summary

Summary written for general audiences

Researchers measured melatonin levels over 24 hours in 20 women with early-stage breast cancer. Women with estrogen receptor positive tumors had significantly lower nighttime melatonin peaks compared to healthy controls, with the lowest melatonin levels corresponding to the highest estrogen receptor concentrations. This suggests disrupted melatonin production may be linked to certain types of breast cancer.

Why This Matters

This 1982 study reveals a critical connection between disrupted melatonin production and estrogen-positive breast cancer that has profound implications for our EMF-saturated world. Melatonin, your body's master antioxidant and sleep hormone, is produced by the pineal gland in response to darkness. The science demonstrates that EMF exposure, particularly the blue light from screens and radiofrequency radiation from wireless devices, suppresses melatonin production by disrupting your circadian rhythms. What this means for you is that chronic EMF exposure may be creating the exact hormonal conditions this study linked to cancer risk. The reality is that modern life bombards us with melatonin-disrupting EMF 24/7, from LED lighting to WiFi routers to cell towers, potentially creating a perfect storm for hormone-dependent cancers.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (1982). Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer.
Show BibTeX
@article{decreased_nocturnal_plasma_melatonin_peak_in_patients_with_estrogen_receptor_positive_breast_cancer_ce1627,
  author = {Unknown},
  title = {Decreased nocturnal plasma melatonin peak in patients with estrogen receptor positive breast cancer},
  year = {1982},
  doi = {10.1126/SCIENCE.7079745},
  
}
DOI: 10.1126/SCIENCE.7079745PubMed: 7079745

Quick Questions About This Study

Yes, this study found women with estrogen receptor positive breast cancer had significantly lower nocturnal melatonin peaks than healthy controls. The correlation was so strong that the lowest melatonin levels corresponded directly with the highest estrogen receptor concentrations in tumors.
The research suggests low nocturnal melatonin concentrations may indicate the presence of estrogen receptor positive breast cancer. The study found this pattern in 10 of 20 breast cancer patients, with significant correlation between melatonin levels and tumor characteristics.
The study suggests low melatonin may have etiologic significance, meaning it could contribute to cancer development rather than just indicating existing disease. Melatonin normally helps regulate estrogen production and has anti-cancer properties, so disrupted production may promote hormone-dependent tumor growth.
The study found the nocturnal melatonin increase was "much lower" in estrogen receptor positive patients compared to controls, though exact percentages weren't specified. The difference was significant enough to establish a clear correlation between melatonin levels and tumor estrogen receptor concentrations.
No, this pattern was specific to estrogen receptor positive breast cancer. The study examined 20 women with stage I or II breast cancer, but the significantly lower melatonin levels were found specifically in the 10 patients whose tumors tested positive for estrogen receptors.